Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
Status:
Recruiting
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of ALXN2050 (120 milligrams [mg], 180 mg) in
participants with generalized myasthenia gravis (gMG).
Safety will be monitored throughout the study.